Rhythm Pharmaceuticals, Inc. (RYTM): who owns it and who trades it
As of Nov 16, 2026, RYTM insiders reported 48 open-market sales worth $36.4M and no purchases in the last 12 months, with 97% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jennifer Kayden Lee (Vice president), with $8.9M. 7 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Rhythm Pharmaceuticals
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns RYTM
303 funds and institutions reported RYTM shares worth $8.6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Ra Capital Management, L.P. with 9.7%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 6.67M | 9.73% | $740M | No change |
| BlackRock, Inc. | 6.16M | 8.98% | $684M | -1% |
| Baker Bros. Advisors LP | 5.60M | 8.18% | $622M | No change |
| Primecap Management Co | 3.17M | 4.62% | $352M | -7% |
| Vanguard Portfolio Management LLC | 3.14M | 4.58% | $348M | +3% |
| Vanguard Capital Management LLC | 3.01M | 4.39% | $334M | +1% |
| JPMorgan Chase & Co | 2.65M | 3.87% | $292M | – |
| Perceptive Advisors LLC | 2.59M | 3.77% | $287M | +9% |
| State Street Corp | 2.57M | 3.76% | $286M | +13% |
| T. Rowe Price Associates | 2.57M | 3.74% | $285M | +55% |
| Westfield Capital Management Co LP | 2.21M | 3.22% | $245M | +14% |
| Goldman Sachs Group Inc | 2.13M | 3.10% | $236M | +8% |
| Federated Hermes, Inc. | 1.79M | 2.61% | $198M | +39% |
| Polar Capital Holdings Plc | 1.66M | 2.43% | $185M | +3% |
| Geode Capital Management, LLC | 1.53M | 2.24% | $170M | +8% |
| Capital Research Global Investors | 1.53M | 2.24% | $170M | +37% |
| Citadel Advisors LLC | 1.26M | 1.84% | $140M | -11% |
| Checkpoint Capital L.P. | 1.19M | 1.73% | $132M | -3% |
| Siren, L.L.C. | 1.14M | 1.66% | $126M | +57% |
| Morgan Stanley | 1.11M | 1.62% | $123M | +58% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, RYTM insiders reported $0 of open-market purchases and $36.4M of sales. 97% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | David P Meeker | CEO | Sale plan | 2,300 | $105.19 | $242K | Form 4 |
| Sep 14, 2026 | David P Meeker | CEO | Sale plan | 6,439 | $101.75 | $655K | Form 4 |
| Sep 14, 2026 | David P Meeker | CEO | Sale plan | 30,746 | $102.35 | $3.1M | Form 4 |
| Sep 14, 2026 | David P Meeker | CEO | Sale plan | 8,698 | $103.43 | $900K | Form 4 |
| Sep 14, 2026 | David P Meeker | CEO | Sale plan | 1,817 | $104.55 | $190K | Form 4 |
| Aug 31, 2026 | Hunter C Smith | CFO | Sale plan | 11,514 | $105.37 | $1.2M | Form 4 |
| Aug 31, 2026 | Hunter C Smith | CFO | Sale plan | 23,072 | $104.59 | $2.4M | Form 4 |
| Aug 31, 2026 | Hunter C Smith | CFO | Sale plan | 28,188 | $106.20 | $3M | Form 4 |
| Aug 13, 2026 | Joseph Shulman | Chief Technical Officer | Sale plan | 5,079 | $119.75 | $608K | Form 4 |
| Aug 13, 2026 | Alastair Garfield | Chief Scientific Officer | Sale plan | 1,556 | $117.08 | $182K | Form 4 |
| Aug 13, 2026 | Alastair Garfield | Chief Scientific Officer | Sale plan | 800 | $119.17 | $95.3K | Form 4 |
| Aug 13, 2026 | Alastair Garfield | Chief Scientific Officer | Sale plan | 2,007 | $116.11 | $233K | Form 4 |
| Aug 13, 2026 | Alastair Garfield | Chief Scientific Officer | Sale plan | 3,400 | $118.28 | $402K | Form 4 |
| Aug 13, 2026 | Jennifer Kayden Lee | Vice president | Sale plan | 75,834 | $117.38 | $8.9M | Form 4 |
| Aug 12, 2026 | Yann Mazabraud | Vice president | Sale plan | 14,568 | $115.43 | $1.7M | Form 4 |
| Aug 12, 2026 | Yann Mazabraud | Vice president | Sale plan | 18,208 | $116.49 | $2.1M | Form 4 |
| Aug 12, 2026 | Yann Mazabraud | Vice president | Sale plan | 17,319 | $117.47 | $2M | Form 4 |
| Aug 12, 2026 | Yann Mazabraud | Vice president | Sale plan | 1,000 | $112.86 | $113K | Form 4 |
| Aug 12, 2026 | Yann Mazabraud | Vice president | Sale plan | 2,300 | $111.80 | $257K | Form 4 |
| Aug 12, 2026 | Yann Mazabraud | Vice president | Sale plan | 3,605 | $114.70 | $413K | Form 4 |
| Jun 22, 2026 | Lynn A. Tetrault | Director | Sale plan | 37,000 | $100.32 | $3.7M | Form 4 |
| May 15, 2026 | Christopher Paul German | Corporate Controller & C | Sale | 4,643 | $92.21 | $428K | Form 4 |
| Mar 4, 2026 | Christopher Paul German | Corporate Controller & C | Sale | 5,614 | $89.56 | $503K | Form 4 |
| Feb 19, 2026 | Hunter C Smith | CFO | Sale plan | 1,308 | $100.27 | $131K | Form 4 |
| Feb 19, 2026 | Hunter C Smith | CFO | Sale plan | 1,692 | $100.92 | $171K | Form 4 |
| Feb 19, 2026 | Hunter C Smith | CFO | Sale plan | 800 | $102.10 | $81.7K | Form 4 |
| Feb 19, 2026 | Hunter C Smith | CFO | Sale plan | 585 | $103.28 | $60.4K | Form 4 |
| Feb 17, 2026 | Hunter C Smith | CFO | Sale plan | 200 | $100.52 | $20.1K | Form 4 |
| Feb 17, 2026 | Hunter C Smith | CFO | Sale plan | 900 | $101.70 | $91.5K | Form 4 |
| Feb 17, 2026 | Hunter C Smith | CFO | Sale plan | 1,069 | $103.00 | $110K | Form 4 |
| Feb 17, 2026 | Hunter C Smith | CFO | Sale plan | 1,200 | $99.42 | $119K | Form 4 |
| Feb 17, 2026 | Hunter C Smith | CFO | Sale plan | 200 | $103.84 | $20.8K | Form 4 |
| Feb 12, 2026 | Hunter C Smith | CFO | Sale plan | 100 | $100.10 | $10K | Form 4 |
| Feb 12, 2026 | Hunter C Smith | CFO | Sale plan | 800 | $98.99 | $79.2K | Form 4 |
| Feb 12, 2026 | Hunter C Smith | CFO | Sale plan | 400 | $97.67 | $39.1K | Form 4 |
| Feb 12, 2026 | Hunter C Smith | CFO | Sale plan | 292 | $96.26 | $28.1K | Form 4 |
| Feb 11, 2026 | Hunter C Smith | CFO | Sale plan | 2,266 | $98.37 | $223K | Form 4 |
| Feb 11, 2026 | Hunter C Smith | CFO | Sale plan | 100 | $100.85 | $10.1K | Form 4 |
| Feb 11, 2026 | Hunter C Smith | CFO | Sale plan | 400 | $99.44 | $39.8K | Form 4 |
| Feb 10, 2026 | Hunter C Smith | CFO | Sale plan | 700 | $103.68 | $72.6K | Form 4 |
| Feb 10, 2026 | Hunter C Smith | CFO | Sale plan | 100 | $104.76 | $10.5K | Form 4 |
| Feb 10, 2026 | Hunter C Smith | CFO | Sale plan | 1,913 | $102.66 | $196K | Form 4 |
| Feb 5, 2026 | Hunter C Smith | CFO | Sale plan | 3,381 | $106.06 | $359K | Form 4 |
| Feb 4, 2026 | Hunter C Smith | CFO | Sale plan | 1,500 | $104.74 | $157K | Form 4 |
| Feb 4, 2026 | Hunter C Smith | CFO | Sale plan | 747 | $107.67 | $80.4K | Form 4 |
| Feb 4, 2026 | Hunter C Smith | CFO | Sale plan | 1,000 | $106.60 | $107K | Form 4 |
| Dec 11, 2025 | Pamela J. Cramer | Chief Human Resources Of | Sale plan | 3,350 | $111.00 | $372K | Form 4 |
| Nov 20, 2025 | Pamela J. Cramer | Chief Human Resources Of | Sale plan | 3,350 | $105.00 | $352K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jennifer Kayden Lee | EVP, Head of North America | – | $8.9M | Aug 13, 2026 |
| Hunter C Smith | Chief Financial Officer | – | $8.8M | Aug 31, 2026 |
| Yann Mazabraud | EVP, Head of International | – | $6.6M | Aug 12, 2026 |
| David P Meeker | President and CEO, Director | – | $5.1M | Sep 14, 2026 |
| Lynn A. Tetrault | Director | – | $3.7M | Jun 22, 2026 |
| Christopher Paul German | Corporate Controller & CAO | – | $931K | May 15, 2026 |
| Alastair Garfield | Chief Scientific Officer | – | $913K | Aug 13, 2026 |
| Pamela J. Cramer | Chief Human Resources Officer | – | $724K | Dec 11, 2025 |
| Joseph Shulman | Chief Technical Officer | – | $608K | Aug 13, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
RYTM short interest
High short interest. 17.0% of RYTM shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 41%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 11.68M RYTM shares were sold short, 17.0% of the shares outstanding, up 6.1% from the report before. At the average daily volume of 500,502 shares, buying them all back would take about 23.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 11.68M | 16.96% | +6% | 500,502 | 23.3 |
| Oct 15, 2026 | 11.00M | 15.98% | +2% | 816,276 | 13.5 |
| Sep 30, 2026 | 10.77M | 15.64% | +5% | 761,706 | 14.1 |
| Sep 15, 2026 | 10.29M | 14.94% | -0% | 512,774 | 20.1 |
| Aug 31, 2026 | 10.30M | 14.96% | +1% | 470,672 | 21.9 |
| Aug 14, 2026 | 10.15M | 14.75% | +8% | 829,841 | 12.2 |
| Jul 31, 2026 | 9.44M | 13.78% | -1% | 583,684 | 16.2 |
| Jul 15, 2026 | 9.57M | 13.97% | -1% | 696,954 | 13.7 |
| Jun 30, 2026 | 9.67M | 14.10% | +21% | 1.28M | 7.6 |
| Jun 15, 2026 | 8.01M | 11.68% | +1% | 691,418 | 11.6 |
| May 29, 2026 | 7.91M | 11.54% | -4% | 535,388 | 14.8 |
| May 15, 2026 | 8.28M | 12.09% | +3% | 1.00M | 8.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Rhythm Pharmaceuticals company events
Rhythm Pharmaceuticals filed 14 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 3, 2026.
- Nov 3, 2026ResultsReleased financial results. Filing
- Aug 4, 2026AnnouncementThe Company announced preliminary data from its ongoing Phase 2 trial evaluating RM-718 in patients with acquired hypothalamic obesity (HO), which are summarized below. Filing
- Jun 25, 2026VoteReported shareholder vote results. Filing
- Jun 15, 2026AnnouncementRhythm announced interim six-month data from its exploratory Phase 2 trial of setmelanotide in patients with PWS, which are summarized below. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Apr 3, 2026LeadershipThe Board of Directors of Rhythm Pharmaceuticals, Inc. elected Kimberly J. Popovits as a non-employee director of the Company, effective on the same date. Filing
- Mar 26, 2026AnnouncementRhythm announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending to expand the current marketing authorization for IMCIVREE ® (setmelanotide) to include the treatment of obesity and the control of hunger in… Filing
- Mar 20, 2026AnnouncementRhythm announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for IMCIVREE® (setmelanotide) to treat patients living with acquired hypothalamic obesity (HO). Filing
- Mar 16, 2026AnnouncementRhythm announced the topline results from its EMANATE trial, which are summarized below. Filing
- Mar 2, 2026AnnouncementRhythm announced additional data from its global Phase 3 TRANSCEND trial of setmelanotide in patients with acquired hypothalamic obesity, which are summarized below. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 9, 2026AnnouncementThe Company announced preliminary unaudited net revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an increase of 11% percent on a sequential basis from the third quarter of 2025. Filing
- Dec 19, 2025LeadershipCamille L. Bedrosian, M.D. notified the Board of Directors of Rhythm Pharmaceuticals, Inc. of her decision to resign from the Board, effective immediately. Filing
- Dec 11, 2025AnnouncementRhythm announced preliminary results from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS), which are summarized below. Rhythm enrolled 18 patients with PWS aged 6-65 years old with a BMI ≥30 kg/m2 for patients ≥18 years of age or BMI ≥95th percentile… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Rhythm Pharmaceuticals financials
Famous investors that hold RYTM
7 of the 50 well-known investors we track reported holding RYTM in their latest 13F filing. The largest position is Steve Cohen's, worth $69.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 726,499 | $69.2M | 0.1% | +75% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 316,973 | $30.2M | 0.0% | -75% |
| Israel Englander · Millennium Management | Q3 2026 | 315,706 | $30.1M | 0.0% | -0% |
| Stanley Druckenmiller · Duquesne Family Office | Q3 2026 | 269,900 | $25.7M | 0.6% | +33% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 105,999 | $10.1M | 0.0% | New |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 95,074 | $9.1M | 0.0% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 88,681 | $8.4M | 0.0% | +30% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named RYTM in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 13, 2026 | JPMORGAN CHASE & CO. | 13G | 5.1% |
| Oct 13, 2026 | JPMORGAN CHASE & CO. | 13G | 5.1% |
Questions about Rhythm Pharmaceuticals, Inc. (RYTM) stock
Who owns the most RYTM stock?
The largest reported owner of Rhythm Pharmaceuticals, Inc. (RYTM) is Ra Capital Management, L.P., with 9.7% of the company. In total, 303 funds and institutions reported holding RYTM at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are RYTM insiders buying or selling?
In the last 12 months, RYTM insiders reported no open-market purchases and 48 sales worth $36.4M. The latest trade was on Sep 14, 2026. See every trade.
What is the short interest in RYTM?
As of Oct 30, 2026, 11.68M RYTM shares were sold short, 17.0% of the shares outstanding, up 6.1% from the report before. At the average daily volume of 500,502 shares, buying them all back would take about 23.3 trading days (days to cover). See the history.
Which famous investors hold RYTM?
7 of the 50 well-known investors we track reported RYTM in their latest 13F filing, including Steve Cohen, Ken Griffin, Israel Englander. The largest position is worth $69.2M. See all holders.
Executive pay
Rhythm Pharmaceuticals's chief executive was paid a total of $17.5M for the year ended Dec 31, 2025, up 20% from $14.7M the year before. In the last 12 months, Rhythm Pharmaceuticals's executives and directors bought no stock on the open market and sold $36.4M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.